Two Sigma Investments LP Has $20.36 Million Stock Position in LivaNova PLC (NASDAQ:LIVN)

Two Sigma Investments LP raised its stake in LivaNova PLC (NASDAQ:LIVN - Free Report) by 27.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 439,582 shares of the company's stock after buying an additional 93,985 shares during the quarter. Two Sigma Investments LP owned about 0.81% of LivaNova worth $20,357,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Sherbrooke Park Advisers LLC bought a new stake in LivaNova in the 4th quarter valued at $378,000. Royal Bank of Canada lifted its holdings in shares of LivaNova by 8.0% in the fourth quarter. Royal Bank of Canada now owns 361,356 shares of the company's stock valued at $16,733,000 after purchasing an additional 26,790 shares in the last quarter. Redmile Group LLC boosted its position in shares of LivaNova by 19.3% during the fourth quarter. Redmile Group LLC now owns 1,043,539 shares of the company's stock worth $48,326,000 after buying an additional 168,500 shares during the period. Point72 Hong Kong Ltd bought a new position in shares of LivaNova during the fourth quarter worth about $715,000. Finally, ProShare Advisors LLC grew its holdings in shares of LivaNova by 41.2% during the fourth quarter. ProShare Advisors LLC now owns 17,902 shares of the company's stock worth $829,000 after buying an additional 5,228 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Analysts Set New Price Targets

LIVN has been the subject of a number of recent research reports. The Goldman Sachs Group reduced their price target on LivaNova from $64.00 to $55.00 and set a "buy" rating for the company in a research report on Monday, March 3rd. Mizuho decreased their target price on shares of LivaNova from $70.00 to $60.00 and set an "outperform" rating for the company in a research report on Wednesday, February 26th. StockNews.com cut shares of LivaNova from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 8th. Needham & Company LLC restated a "buy" rating and issued a $64.00 price objective on shares of LivaNova in a report on Tuesday, May 13th. Finally, Robert W. Baird lifted their target price on LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a research report on Thursday, May 8th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $59.29.

LivaNova Stock Performance

Shares of LIVN opened at $43.66 on Thursday. The company has a market cap of $2.38 billion, a PE ratio of 103.95 and a beta of 0.84. The firm has a 50-day moving average of $38.70 and a 200-day moving average of $44.75. LivaNova PLC has a one year low of $32.48 and a one year high of $61.94. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.